Fiscal 2026 July Term Financial Summary [Japanese GAAP] (Consolidated)

Overview of Results

For the consolidated results for the fiscal year ending July 2026, net sales declined to 13,883 million yen (down 14.1% from the prior year). Operating profit declined to 494 million yen (down 19.8%), while ordinary income was 602 million yen (down 0.5%), remaining broadly flat. Net income attributable to owners of the parent fell to 364 million yen (down 22.8%). By segment, the Anti-Aging business saw a decrease in sales, while the Recovery business maintained growth. Going forward, under the 'Skin for Longevity' strategy, the company will strengthen the dual-brand expansion and group collaboration in the Recovery business.

Outlook and Cash Flow

For the consolidated results of the year ending July 2027, the company projects net sales of 13,500 million yen (down 2.8% YoY), operating profit of 100 million yen (down 80.0%), ordinary income of 100 million yen (down 83.4%), and net income attributable to owners of the parent of 100 million yen (down 72.5%). At year-end, cash and cash equivalents are expected to be 4,951 million yen. Looking ahead, amid rising individual spending and inbound demand, the company aims to restore sales through brand value enhancement and optimization of the channel mix.